|Awarded On||August 20, 2014|
|Title||Investigating and Preclinical Targeting Molecular Drivers of Muscle-Invasive Bladder Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Keith Chan|
Bladder cancer is the fifth most common cancer and the most expensive cancer to treat (i.e. cost per patient) in the United States. In the past thirty years, there has been no major improvement in the survival of patients with muscle-invasive bladder cancer, since surgical removal of the entire bladder and chemotherapy still remain the major treatment options. Thus far, no specific therapy other than conventional therapy (e.g. chemotherapy, radiation) is clinically approved to treat invasive bladder cancer, since the genetic causes for invasion remains largely unknown. While other possible genetic causes were intensively studied and shown to be associated with human invasive bladder cancers ...